Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Joseph Baroldi Sells 4,006 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Joseph Baroldi sold 4,006 shares of the company’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total value of $166,649.60. Following the sale, the executive vice president now owns 19,631 shares in the company, valued at $816,649.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS opened at $40.91 on Thursday. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $34.32 and a fifty-two week high of $54.44. The company has a debt-to-equity ratio of 3.18, a current ratio of 5.90 and a quick ratio of 5.83. The business has a 50 day moving average price of $44.25 and a 200-day moving average price of $47.35.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, February 21st. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.72. The firm had revenue of $325.00 million during the quarter, compared to analyst estimates of $176.01 million. Ionis Pharmaceuticals had a negative return on equity of 90.29% and a negative net margin of 46.32%. The business’s quarterly revenue was up 113.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.37) earnings per share. Equities analysts forecast that Ionis Pharmaceuticals, Inc. will post -4 earnings per share for the current year.

Wall Street Analyst Weigh In

IONS has been the topic of several analyst reports. William Blair reiterated an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 9th. Bank of America upgraded Ionis Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the company from $52.00 to $62.00 in a research report on Tuesday, January 2nd. Royal Bank of Canada upped their price objective on shares of Ionis Pharmaceuticals from $65.00 to $70.00 and gave the stock an “outperform” rating in a research report on Friday, January 26th. Wolfe Research upgraded shares of Ionis Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $58.00 price objective on the stock in a research report on Wednesday, April 10th. Finally, Oppenheimer upped their price objective on shares of Ionis Pharmaceuticals from $72.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $56.08.

Institutional Trading of Ionis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. PNC Financial Services Group Inc. boosted its stake in shares of Ionis Pharmaceuticals by 2.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,378 shares of the company’s stock valued at $424,000 after purchasing an additional 202 shares during the period. Grandfield & Dodd LLC raised its holdings in shares of Ionis Pharmaceuticals by 0.7% during the fourth quarter. Grandfield & Dodd LLC now owns 33,104 shares of the company’s stock valued at $1,675,000 after acquiring an additional 242 shares in the last quarter. Captrust Financial Advisors raised its holdings in shares of Ionis Pharmaceuticals by 21.1% during the second quarter. Captrust Financial Advisors now owns 1,429 shares of the company’s stock valued at $53,000 after acquiring an additional 249 shares in the last quarter. Treasurer of the State of North Carolina raised its holdings in shares of Ionis Pharmaceuticals by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 62,532 shares of the company’s stock valued at $2,836,000 after acquiring an additional 310 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of Ionis Pharmaceuticals by 2.3% during the third quarter. Victory Capital Management Inc. now owns 15,436 shares of the company’s stock valued at $700,000 after acquiring an additional 348 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.